Matinas BioPharma (MTNB) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St ends mixed as oil takes a pause
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Matinas BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
March 29, 2021 6:30 AM EDTMatinas to internally focus on its Lipid Nanocrystal (LNC) platform to improve the intracellular delivery of critical therapeutics
Enrollment continues in second patient cohort of EnACT study of MAT2203 in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) evaluation of safety and efficacy data of key second patient cohort anticipated Q3 2021
Collaboration with National Institute of Allergy and Infectious Disease (NIAID) to formulate Gileads antiviral COVID-19 medication remdesivir has progressed into in vitro studies
Data from ENHANCE-IT study of LYPDISO against Vascepa® support continued development of LYPDISO as a... More
